Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1091

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 7
Chunk 1091
---
 equivalent payments for net share settlement of restricted stock units 
     (18,927) 
     (34,778)
  
    Net proceeds from the issuance of common stock 
     3,539,907  
     1,322,383 
  
    Proceeds from exercise of warrants – standard terms 
     2,054,940  
     – 
  
    Proceeds from exercise of warrants – induced terms 
     2,316,320  
     – 
  
    Commission paid related to warrant inducement 
     (153,979) 
     – 
  
    Legal fees paid related to warrant inducement 
     (10,877) 
     – 
  
    Net cash provided by financing activities 
     7,727,384  
     1,287,605 

    Effect of Exchange Rate on Changes on Cash 
     (12,262) 
     2,107 

    Net increase (decrease) in cash and cash equivalents and restricted cash 
     69,590  
     (9,090,965)

    Cash and cash equivalents restricted cash at beginning of year 
     5,529,484  
     14,620,449 

    Cash and cash equivalents and restricted cash at end of year 
    $5,599,074  
    $5,529,484 

    Supplemental information of non-cash investing and financing activities: 

    Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services 
    $13  
    $35 
  
    Disposal of fully depreciated property 
    $350,670  
    $– 
  
    Reversal of accrued commission liability (see Note 6) 
    $–  
    $404,120 
  
    Deferred offering costs not yet paid 
    $–  
    $219,117 

    Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: 

    Cash and cash equivalents 
    $5,501,261  
    $5,441,978 
  
    Restricted cash 
     97,813  
     87,506 
  
    Cash and restricted cash 
    $5,599,074  
    $5,529,484 

See accompanying notes to the consolidated financial
statements.

 F-